491 related articles for article (PubMed ID: 34216998)
1. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
[TBL] [Abstract][Full Text] [Related]
2. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
[TBL] [Abstract][Full Text] [Related]
4. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
[TBL] [Abstract][Full Text] [Related]
5. Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.
Shaygannejad V; Afshari-Safavi A; Hatef B
Neurol Sci; 2021 Jul; 42(7):2891-2901. PubMed ID: 33219424
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
[TBL] [Abstract][Full Text] [Related]
8. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
11. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
Maillart E; Papeix C; Lubetzki C; Roux T; Pourcher V; Louapre C
Mult Scler Relat Disord; 2020 Nov; 46():102482. PubMed ID: 32916509
[TBL] [Abstract][Full Text] [Related]
12. Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea.
Kim H; Park KA; Oh SY; Min JH; Kim BJ
Korean J Ophthalmol; 2019 Feb; 33(1):82-90. PubMed ID: 30746915
[TBL] [Abstract][Full Text] [Related]
13. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
[TBL] [Abstract][Full Text] [Related]
14. Risk of fracture in neuromyelitis optica spectrum disorder and multiple sclerosis: a nationwide cohort study in South Korea.
Jung SY; Cho EB; Han KD; Jung JH; Yeo Y; Kong SH; Shin DW; Min JH
Osteoporos Int; 2023 May; 34(5):925-933. PubMed ID: 36854747
[TBL] [Abstract][Full Text] [Related]
15. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D
Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085
[TBL] [Abstract][Full Text] [Related]
16. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Tomczak A; Han MH
Mult Scler Relat Disord; 2020 Oct; 45():102347. PubMed ID: 32645636
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.
Kim SH; Kwak K; Jeong IH; Hyun JW; Jo HJ; Joung A; Yu ES; Kim JH; Lee SH; Yun S; Joo J; Lee DK; Lee JM; Kim HJ
Mult Scler; 2016 Dec; 22(14):1850-1858. PubMed ID: 26920380
[TBL] [Abstract][Full Text] [Related]
18. A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
Viswanathan S; Wah LM
Mult Scler; 2019 Oct; 25(11):1452-1461. PubMed ID: 30113245
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS
Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
Newsome SD; Cross AH; Fox RJ; Halper J; Kanellis P; Bebo B; Li D; Cutter GR; Rammohan KW; Salter A
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
